Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON45317
NL-OMON45317
Completed
Phase 3

Prostate Cancer Imaging with [18Flourine]Prostate Specific Membrane Antigen (PSMA) PET: a study on pharmacokinetics and test repeatability - Pharmacokinetics and repeatability of [18F]PSMA

Vrije Universiteit Medisch Centrum0 sites20 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsprostate cancerprostate malignancyneoplasm of the prostate10038597

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
prostate cancer
Sponsor
Vrije Universiteit Medisch Centrum
Enrollment
20
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • •\- Histologically proven prostate cancer, with lymphatic and/or haematogeneous metastases;
  • •\- Written informed consent;
  • •\- At least 2 metastases in the thorax per patient detected by conventional imaging (e.g., bone scan, either CT or MRI of the chest, abdomen and pelvis); conventional imaging should be recently performed (no longer than 3 months previous to the PET\-CT scan);
  • •\- At least one tumour (metastasis) with diameter \* 1\.5 cm (to minimize partial volume effects);
  • •\- Patients able to remain supine for 60 minutes in the PET\-CT scanner;;Part B;
  • •\- Histologically proven prostate cancer, with lymphatic and/or haematogeneous metastases;
  • •\- Written informed consent;
  • •\- At least one tumour (metastasis) with diameter \>1\.5 cm detected by recently performed conventional imaging (maximal 3 months prior to the PET\-CT scan);
  • •\- Patients able to remain supine for 80 minutes in the PET\-CT scanner;

Exclusion Criteria

  • •A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • •\- Claustrophobia (part A and B);
  • •\- Multiple malignancies (part A and B);
  • •\- Participation part A (Part B)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
The PSMA-PET scan: a study on tracer properties and test repeatability(metastasized) prostate cancer(gemetastaseerde) prostaatkanker
NL-OMON24408VU University Medical Center, Amsterdam20
Recruiting
Not Applicable
Evaluation of new PET tracer, [F-18]Florastamin for diagnosing prostate cancerNeoplasms
KCT0003924Korea Cancer Center Hospital6
Active, not recruiting
Not Applicable
Diagnostic imaging in prostate cancer (as in tumours with accelerated menbrane turn-over)by F-18 Fluoro-metil-choline PET/CTpatients with prostate cancer istologically provenMedDRA version: 14.1Level: SOCClassification code 10038359Term: Renal and urinary disordersSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 14.1Level: SOCClassification code 10022891Term: InvestigationsSystem Organ Class: 10022891 - InvestigationsTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2008-003337-24-ITCENTRO DI RIFERIMENTO ONCOLOGICO DI BASILICATA
Recruiting
Not Applicable
Evaluation of new PET tracer, [F-18]Florastamin for diagnosing prostate cancer: Phase I clinical trial
KCT0004817FutureChem10
Recruiting
Not Applicable
Imaging of Metastatic Prostate Cancer Tumors Using 68Ga-NTA-14Metastatic Prostate CancerCancer - Prostate
ACTRN12621001704886St. Vincent's Hospital Sydney Limited10